Really interesting here... - be a little bit nervous, if still...

Really interesting here...

- be a little bit nervous, if still waiting around - to take a position in the company, pending this DIPG data release.

Why so ?  Well this company, Day One Pharmaceuticals - also has its kids brain cancer study sponsored by The Pacific Pediatric Neuro-Oncology Consortium (PNOC)......Ony a few weeks ago - Day One just came out and made a data announcement for their FDA Trial - no waiting around for a conference presentation, just a simple stock exchange announcement.

Sent the market cap up by A$400 million or so  - mind numbing, considering they had already been capped at a billion.

So we are entering into a "hold your breath period" for this company - given a previous delay in release of DIPG data, and the company clearly saying to expect it in July or August.

There would be great justification for a share price 15 times higher than currently - should DIPG data be positive - so 15 times, or A$400m cap, that is still pretty ridiculously cheap though.




ASCO: Day One Biopharma announces new FIREFLY-1 data for tovorafenib


06-06-2023
Day One Biopharmaceuticals (Nasdaq: DAWN) shares leapt 33.8% to $18.19 in pre-market trading on Monday, after the company announced overall response rate of 67% and clinical benefit rate of 93% in 69 heavily pre-treated RANO-HGG evaluable patients in pediatric low-grade glioma trial.

Day One Bio shared the new data from its Phase II registrational FIREFLY-1 trial evaluating tovorafenib (DAY101) for relapsed or progressive pediatric low-grade glioma..........